- Home
- ENGN vs SMLR Comparison
ENGN vs SMLR Comparison
Compare ENGN & SMLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- SMLR
- Stock Information
- Founded
- ENGN 1999
- SMLR 2007
- Country
- ENGN Canada
- SMLR United States
- Employees
- ENGN N/A
- SMLR N/A
- Industry
- ENGN
- SMLR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ENGN
- SMLR Health Care
- Exchange
- ENGN Nasdaq
- SMLR Nasdaq
- Market Cap
- ENGN 293.1M
- SMLR 289.5M
- IPO Year
- ENGN N/A
- SMLR 2014
- Fundamental
- Price
- ENGN $8.57
- SMLR $63.40
- Analyst Decision
- ENGN Strong Buy
- SMLR
- Analyst Count
- ENGN 8
- SMLR 0
- Target Price
- ENGN $30.38
- SMLR N/A
- AVG Volume (30 Days)
- ENGN 142.9K
- SMLR 1.1M
- Earning Date
- ENGN 01-27-2025
- SMLR 11-04-2024
- Dividend Yield
- ENGN N/A
- SMLR N/A
- EPS Growth
- ENGN N/A
- SMLR N/A
- EPS
- ENGN N/A
- SMLR 2.04
- Revenue
- ENGN N/A
- SMLR $58,938,000.00
- Revenue This Year
- ENGN N/A
- SMLR N/A
- Revenue Next Year
- ENGN N/A
- SMLR N/A
- P/E Ratio
- ENGN N/A
- SMLR $31.22
- Revenue Growth
- ENGN N/A
- SMLR N/A
- 52 Week Low
- ENGN $4.42
- SMLR $20.88
- 52 Week High
- ENGN $18.40
- SMLR $79.45
- Technical
- Relative Strength Index (RSI)
- ENGN 55.84
- SMLR 64.58
- Support Level
- ENGN $8.00
- SMLR $56.75
- Resistance Level
- ENGN $9.60
- SMLR $63.29
- Average True Range (ATR)
- ENGN 0.62
- SMLR 8.48
- MACD
- ENGN 0.05
- SMLR 0.24
- Stochastic Oscillator
- ENGN 55.22
- SMLR 55.76
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About SMLR Semler Scientific Inc.
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.